Filter trials by:

Year

Indication

Phase

Type

Type: Pharmaceutical - Pain

A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation and noninferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking 50/25 – 80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 – 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone.
  • Year: 2012
  • Type: Pharmaceutical - Pain
  • Phase: III
  • Indication: Pain - General
A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration.
  • Year: 2013
  • Type: Pharmaceutical - Pain
  • Phase: I, IIa
  • Indication: Back and/or Leg Pain
A Randomized, Double-Blind, Crossover, Phase IIa Study Comparing a Single-Application TPM®/Oxycodone Patch versus Vehicle Patch in the Topical Treatment of Patients with Postherpetic Neuralgia.
  • Year: 2015
  • Type: Pharmaceutical - Pain
  • Phase: IIa
  • Indication: Postherpetic Neuralgia
CREATE-1: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I).
  • Year: 2016
  • Type: Pharmaceutical - Pain
  • Phase: III
  • Indication: CRPS
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of topical Lidocaine Spray in Patients with Postherpetic Neuralgia.
  • Year: 2018
  • Type: Pharmaceutical - Pain
  • Phase: II
  • Indication: Postherpetic Neuralgia
A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE).
  • Year: 2018
  • Type: Pharmaceutical - Pain
  • Phase: II
  • Indication: Painful Diabetic Neuropathy

CONNECT WITH US

Facebook Linkedin Instagram Envelope Phone

CONTACT US

CovidSafe - Newcastle Research Institute - Genesis Research Services

Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.